紫外分光光度法测定尼美舒利栓中尼美舒利含量

目的建立用紫外分光光度法测定尼美舒利栓中尼美舒利的含量。方法用不同的有机溶剂萃取尼美舒利栓中的基质,用紫外分光光度法测定尼美舒利的含量。结果用正己烷作为萃取剂,回收率高(94.4%)。用紫外分光光度法测定尼美舒利栓的含量,标准曲线线性好(r=0.9999)、精密度高(日内RSD=0.47%)、回收率高(98.3%)。结论用紫外分光光度法测定尼美舒利栓剂的含量,方法简便、快速、结果准确,可作为尼美舒利含量测定的方法。     

紫外分光光度法测定氟尿嘧啶栓中氟尿嘧啶的含量

目的建立氟尿嘧啶栓剂中氟尿嘧啶含量测定方法。方法用紫外分光光度法测定氟尿嘧啶栓剂中氟尿嘧啶的含量。结果平均回收率为100.20%，RSD＝1.1%。结论该法快速、准确，可作为氟尿嘧啶栓剂的含量测定方法。     

紫外分光光度法测定尼美舒利栓的含量

目的 :建立用紫外分光光度法测定尼美舒利栓中尼美舒利的含量。方法 :用不同的有机溶剂萃取尼美舒利栓中的基质 ,用紫外分光光度法测定尼美舒利的含量。结果 :用正己烷作为萃取剂。用紫外分光光度法测定尼美舒利栓的含量 ,标准曲线线性好尼美舒利线性范围为 3～ 15 μg·ml-1(r =0 .9999)、回收率较好 (98.3% )。结论 :用紫外分光光度法测定尼美舒利栓剂的含量 ,方法简便、快速、结果准确 ,可作为尼美舒利含量测定的方法。     

紫外分光光度法测定达那唑栓剂的含量

本文报道用紫外分光光度法在２８５ｎｍ波长处测定达那唑栓剂中达那唑的含量。该方法平均回收率和ＲＳＤ分别为９９．８％和０．６２％，结果表明紫外分光光度法可用于达那唑栓剂中的达那唑含量测定。     

氧氟沙星栓的制备与含量测定

本文报道了用脂溶性栓剂基质制备氧氟沙星栓剂及栓剂的质控方法。并用单波长紫外分光光度法测定栓剂中氧氟沙星的含量,结果满意。     

双氯灭痛微囊的含量测定及体外溶出度观察

本文利用紫外分光光度法测定双氯灭痛微囊含量，并对双氯灭痛微囊及肠溶片进行体外溶出度测定比较。实验结果表明，双氯灭痛微囊与肠溶片Ｔ５０、Ｔ４比较具有显著差异（ｐ＜０．０５），表明双氯灭痛微囊具有明显的缓释作用，延长药物作用时间，这为其制备长效制剂提供了依据。     

紫外分光光度法测定双氯灭痛滴眼液的含量

本文采用紫外分光光度法测定了双氯灭痛滴眼液的含量,方法简便迅速,回收率高,重现性好     

酮康唑栓剂的制备及质量控制

目的:制备酮康唑栓剂,制定质量控制标准。方法:以S-40为栓剂基质,酮康唑为主药,制备栓剂,并用紫外分光光度法测定含量。结果:该栓剂质量稳定,无局部刺激性,酮康唑平均回收率为100.51%(n=5),RSD为0.52%。结论:酮康唑栓剂制备工艺简单,含量测定操作简便、结果准确。     

盐酸芦氟沙星阴道栓的制备与质量控制

目的:研制盐酸芦氟沙星阴道栓并对其质量进行控制.方法:以明胶、甘油为基质制备该栓剂,用紫外分光光度法测定盐酸芦氟沙星的含量.结果:盐酸芦氟沙星含量测定的标准曲线为C=41.1A-0.396(r=0.999 6,n=5),平均回收率为100.4%,RSD为1.02%(n=5).结论:该栓剂处方合理,质控方法可靠.     

吡喹酮水凝胶栓剂的含量测定

目的:制备吡喹酮水凝胶栓剂,并建立其含量测定方法。方法:用紫外分光光度法测定凝胶栓剂中吡喹酮的含量。结果:吡喹酮在0.2￣1.0mg/ml(r=0.9999)浓度范围内呈良好线性关系。平均加样回收率和相对标准偏差(RSD)为(102.44±0.69)%。结论:该处方设计合理,制备工艺可靠,质量稳定。     

Absorption and Bioavailability of Diclofenac after Rectal Administration of Diclofenac-Na Gel Preparation in Rat and Man

In order to evaluate diclofenac-Na (DC-Na) micro-enema, DC-Na gel preparations were administered to rats and man. When DC-Na gel preparations were rectally administered at various pH (pH 5– 8) to rats, their bioavailability increased at higher pH. The bioavailability of DC-Na gel preparations (pH 8.0) in rats was significantly higher than that with conventional suppository bases, Witepsol H-15 and polyethylene glycol 1000 (PEG 1000). In man, the DC-Na gel preparation showed higher C_max and higher bioavailability than commercial suppository made with an oily base. DC-Na gel preparations containing 10% v/v oleic acid showed a prolonged action. The irritative effect of DC-Na gel preparation on rectal mucosa in rats was weaker than that of PEG 1000, but similar to that of Witepsol H-15. Therefore, the present results suggest that gel preparation is a favorable form for rectal administration of diclofenac-Na.     

Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema

Objectives Diclofenac is a non-steroidal anti-inflammatory drug used for a variety of painful and inflammatory conditions. A new low-dose, topical-gel form of diclofenac sodium (diclofenac-Na) has been developed for pain relief and redness reduction after sunburn. The objective was to compare exposure to oral diclofenac-Na with the systemic exposure to diclofenac after application of the new topical diclofenac-Na 0.1% Emulgel gel (diclofenac-Na gel) to normal skin and to that with ultraviolet-induced erythema relative. Methods This study was an open, single-centre, three-period, non-randomised trial in 18 healthy Caucasian subjects. During the first period, 12.5 g gel (12.5 mg diclofenac-Na) was applied twice on a single day to normal skin. During the second period, a 25-mg diclofenac-Na, enteric-coated tablet was given orally three times in a single day. During the third period, the diclofenac-Na gel was applied, as in the first period, but during the early phase of an erythema induced by three times the ultraviolet minimal erythema dose, i.e. a first-degree sunburn associated with pain. During each period, venous blood samples were collected over 24 h and urine was collected over 72 h after first administration for the determination of diclofenac in plasma and urine and of 4-OH-diclofenac in urine. Results The systemic exposure after topical application of 25 mg diclofenac-Na on sunburned skin was less than 3% that of 75 mg oral diclofenac-Na and was not increased to that measured on normal skin. Conclusion The diclofenac-Na 0.1% Emulgel gel can be applied safely to sunburned skin (superficial sunburn, i.e. first degree) as well as to normal skin.     

紫外分光光度法测定制霉素栓中制霉素含量

目的建立制霉素栓中制霉素的含量测定方法。方法用乙醚萃取栓剂基质，用紫外分光光度法在304nm波长处测定制霉素栓的含量。结果制霉素质量浓度在10～200U／mL范围内与吸收度呈良好的线性关系，平均回收率为98.28％，RSD为1．38％。结论所用含量测定方法简便、快速、准确，适用于制霉素栓中制霉素的含量测定。     

复方加替沙星妇科栓的制备及质量控制

目的根据临床需求制备以加替沙星和奥硝唑为主药的妇科栓并建立质量控制标准。方法以硬脂酸聚烃氧(40)酯(S-40)为主基质,用热熔法制备。采用双波长紫外分光法测定栓剂中加替沙星和奥硝唑的含量。结果加替沙星和奥硝唑的平均回收率分别为99.36%(RSD=1.37%)和101.05%(RSD=0.86%),成品稳定性好,刺激性小。结论该栓剂制备方法简便,质量控制准确,适合作为医院制剂推广。     

苦豆子栓剂的研制及临床应用

目的 :研制治疗慢性前列腺炎的栓剂并考察其临床疗效。方法 :以苦豆子总生物碱 (TASa)为主药 ,用酸性染料分光光度法测定TASa的含量 ,并与前列安栓进行对照 ,观察其临床疗效。结果 :TASa的线性范围为0 14～15 4μg/ml,氧化苦参碱对照品的加样回收率为101 2 % ,RSD=0 55 %。结论 :该制剂制备工艺简单 ,质控方法可靠 ;对直肠刺激性小 ,临床疗效确切 ,值得临床推广应用。     

双氯芬酸钠中空栓的制备及质量控制

目的:制备双氯芬酸钠中空栓并建立其质量控制方法。方法:以混合脂肪酸甘油酯为基质制备中空栓,采用紫外分光光度法测定其中主药的含量。结果:所制备制剂为乳白色栓剂;双氯芬酸钠检测浓度的线性范围为5～25μg·mL-1(r=0.9997),平均回收率为102.04%(RSD=1.08%)。结论:该制剂制备工艺简便可行,质量稳定可控。     

奥硝唑中空栓的制备及质量控制

目的:制备奥硝唑中空栓并建立其质量控制方法。方法:以半合成脂肪酸甘油酯为基质制成中空栓;采用紫外分光光度法测定主药奥硝唑含量,测定波长为316nm。结果:奥硝唑检测浓度在6.0~18.0μg/ml范围内线性关系良好(r=0.9 997),平均回收率为99.80%(RSD=0.75%,n=5)。结论:本方法简便、准确、重现性好,可用于奥硝唑中空栓的质量控制。     

奥硝唑生物粘附性缓释栓的制备及质量控制

目的：制备治疗滴虫感染的奥硝唑生物粘附性缓释栓，并制定其质量控制标准。方法：以PEG—600，PEG—6000，CMC—Na为栓剂基质，奥硝唑为主药制成栓剂，并用紫外分光光度法测定主药的含量。结果：低、中、高3种浓度的平均回收率分别为99.92％，98．76％，100．61％，RSD分别为0．08％，1．24％，0．61％。结论：奥硝唑生物粘附性缓释栓制备工艺简单，栓剂成型性好，含量剩定方法可行，结果可靠。